Newsletter · 2026-06-26 · Ashutosh Agarwal

Healthcare Weekly - Week of June 26, 2026: Medicare's GLP-1 Bridge Goes Live, M&A Supercycle Accelerates

Healthcare and biopharma newsletter for the week of June 20 to 26, 2026. The CMS Medicare GLP-1 Bridge Program goes live July 1 at a $50 monthly co-pay, the biopharma M&A supercycle accelerated with AbbVie's $10.9B Apogee deal and a flurry of Lilly transactions, and policy overhang from 340B, IRA and MFN pricing framed the bear case.

Healthcare Podcast Weekly Digest

Week of June 26, 2026: Medicare's GLP-1 Bridge Goes Live, M&A Supercycle Accelerates

1. Opening Summary

Healthcare was dominated this week by one near-term catalyst above all others: the CMS Medicare GLP-1 Bridge Program, which goes live July 1 and for the first time gives Medicare Part D beneficiaries broad coverage of obesity drugs at a $50/month co-pay, a structural demand unlock for Eli Lilly and Novo Nordisk that ran through nearly every podcast. Underneath that, the biopharma M&A supercycle accelerated (AbbVie/Apogee at $10.9B, plus a flurry of Lilly deals), retatrutide's surgery-level Phase 3 weight-loss data reset the bull case on Lilly, and policy overhang (340B, IRA price negotiation, MFN pricing) framed the bear case for the broader group. Sell-side tone is constructive, with UNH price target lifted into Q2 earnings and Lilly targets pushed toward $1,232, and several voices flagged a rotation out of AI/tech and into defensive healthcare and small-cap pharma.

2. Key People This Week

3. Hot Topics

GLP-1 / obesity, the center of gravity. The Medicare GLP-1 Bridge Program (effective July 1) covers Wegovy, Zepbound and Lilly's Foundayo: patient pays $50/month, government pays manufacturers ~$245–254/month, potential reach up to 60 million Medicare patients (On The Pen, Jun 23; The Dr. Francavilla Show, Jun 22). Lilly confirmed the operational details on Jun 25: Part D patients meeting clinical criteria can access Foundayo or Zepbound KwikPen at $50/month, coverage running through Dec 31, 2027. GLP-1s now exceed 20% of total prescription spend at some large pharmacy coalitions (Actuary Voices, Jun 25), and ~13.7% of US adults currently use them with another ~20% interested (Bake to the Future, Jun 22).

Eli Lilly (LLY). Retatrutide (triple agonist) Phase 3 Triumph 1: mean 28.3% body weight loss over 80 weeks, with 62.5% of 12mg patients hitting ≥25% loss, surgery-level efficacy (The Obesity Guide, Jun 22). Multiple investor podcasts hold LLY and call it "the best-run large pharma," with tirzepatide patents to 2036 and $12.8B combined Q1 2026 tirzepatide revenue (Mounjaro $8.66B, +100% YoY; Zepbound $4.16B) (Motley Fool Hidden Gems, Jun 23). News flow corroborated an aggressive dealmaking cadence: 4E Therapeutics (chronic pain), Centessa ($7.8B, UK court-approved Jun 22), a $1.9B Abbisko collaboration, BioArctic ($30M upfront/up to $770M), and stalking-horse bids for bankrupt Sangamo's assets. Sell-side targets climbing: Leerink to $1,232 (Outperform, Jun 25), Berenberg to $1,135 (Hold, Jun 22).

AbbVie (ABBV). Acquiring Apogee Therapeutics for $10.9B for IL-13 blocker Zumiloki (atopic dermatitis), which carries a ~3-month dosing advantage vs Dupixent, a direct patent-cliff fill as Humira fell ~40% YoY to $688M in Q1 2026 while Skyrizi (+31%) and Rinvoq (+23%) take over (BioCentury, Jun 23; BioSpace, Jun 24).

UnitedHealth (UNH). Operationally, $3B AI push via Optum Insight and the "Avery" concierge (targeted at 20.5M members) (Becker's, Jun 23). On the tape, BofA raised its target to $475 (Buy) into Q2 earnings, citing better cost-trend visibility, but UNH is also named among insurers swept into the DOJ's $6.5B healthcare fraud enforcement action (WSJ, Jun 23).

4. Key Debates (Bull vs. Bear)

GLP-1: unlimited growth vs. adherence/access ceiling

• Bull: 60M Medicare patients newly eligible July 1; expanding indications (CV, liver, fertility); retatrutide nearing bariatric-surgery efficacy; social ROI cited at $3.81 per dollar (Medicaid) (DOC Updates, Jun 24).
• Bear: only 25–35% of patients persist at one year; Bridge implementation is complex with post-2027 access uncertain; current ~13.7% penetration implies a real execution gap.

AbbVie: patent-cliff recovery vs. further erosion

• Bull: Skyrizi/Rinvoq momentum; Apogee adds a potential mega-blockbuster in dermatology.
• Bear: Humira -40%; $10.9B for a still-Phase-2 asset; 340B/IRA pricing compress economics.

FDA: friend or foe to gene therapy

• Emerging view: a "reversal train," UniQure (AMT-130, Huntington's, BLA planned Q3 using natural-history comparators) and Regenxbio both got renewed paths after earlier demanding control-arm requirements (BioCentury, Jun 23; BioSpace, Jun 24).
• Risk: accelerated approvals on natural-history comparators may invite post-marketing scrutiny.

China biopharma: dealmaking opportunity vs. geopolitical/tariff risk

• Bull: 30% of global licensed assets now from China; quality rising (BeiGene BTK, Akeso PD-1/VEGF).
• Bear: tariff environment explicitly flagged as complicating deal modeling (The BioCentury Show, Jun 25).

Policy: biopharma "nuclear winter" vs. manageable

• Bear: 340B + IRA + MFN pricing compounding; 40% of oncology drugs through 340B; cited 35% cut to oncology research investment (Vital Health, Jun 25).
• Counter: specialty pharma with approved, growing drugs (e.g., Prial's Axelom) seen as insulated.

5. Emerging Themes

• Rotation into healthcare / small-cap pharma as a defensive play out of AI/tech (Schwab Network, Jun 23; Stock Market Today With IBD, Jun 25).
• AI as a pharma cost/speed lever, Lilly's TuneLab/TrueLab (with NVIDIA) and a Charles River collaboration; Sandbox AQ + NVIDIA compressing GPCR screening from years to weeks (Squawk on the Street, Jun 23); AlphaFold/Isomorphic Labs on structure prediction (Machine Learning Street Talk, Jun 22).
• Clinical AI with hard ROI, Cleveland Clinic + Bayesian Health sepsis detection cited at a 41% mortality drop (What's Your Problem?, Jun 25).
• GLP-1 second-order winners, cold-chain logistics (UPS investing $48M in 27 temperature-controlled facilities); food companies (GLP-1 users shop more frequently, not less) (Brew Markets / Bake to the Future, Jun 22).
• Cellular therapy momentum at ASCO 2026, OBX115 modified TIL at 67% response in melanoma; TIL-score basket trial at 50% in pancreatic cancer (ASCO Daily News, Jun 24).

6. Deals & M&A Tracker

Context: H1 2026 pharma/biotech M&A is on pace for a record year with 20+ deals above $1B; Q1 deal value reportedly topped $65B, driven by ~$300B of branded loss-of-exclusivity exposure this decade (PwC, Jun 17–24; Fierce Pharma, Jun 17). Physician-practice-management M&A is busier but more selective than the 2020–21 peak, favoring women's health, urology, MSK/ortho, cardiology, GI and dental (Becker Private Equity, Jun 25).

7. Regulatory Watch

• Medicare GLP-1 Bridge Program launches July 1, first broad Medicare Part D coverage of GLP-1s for obesity; $50/month patient cost; runs through Dec 31, 2027 (Lilly, Jun 25; CMS extension via Medicare Rights, Jun 4).
• FDA gene-therapy reversals, UniQure AMT-130 (Huntington's) BLA planned Q3 on natural-history comparators; Regenxbio (MPS) also reversed (BioCentury/BioSpace, Jun 23–24).
• FDA enforcement, coordinated batch of ~25 warning letters to telehealth firms over misleading DTC ads for compounded GLP-1s, week of Jun 15 (Sheppard Mullin, Jun 18). New approvals noted: Datroway (TNBC, Daiichi/AZN), Xocova (oral COVID prophylactic, Shionogi), Hepcludex (Hep D, Gilead).
• IRA drug-price negotiation, CMS published its first proposed rule for the 2029 IPAY cycle on Jun 12, moving from guidance to formal rulemaking; Small Biotech Exception sunsets after 2028 with a proposed temporary pricing floor (~66% of Non-Federal AMP) for 2029–2030 (Holland & Knight, Jun 18).
• MFN / GLOBE model, mandatory Global Benchmark model slated to begin Oct 1, 2026, importing Most Favored Nation pricing into Part B (ISPOR, Jun 13).
• 340B, HRSA reimplementing a rebate model for negotiated drugs in 2026–27; flagged as a major biopharma headwind (Achieving Health, Jun 24; Vital Health, Jun 25).
• DOJ, $6.5B healthcare fraud sweep (~450 defendants), with new FTC/DHS/CMS data-sharing; managed-care names including UNH, CVS, CNC, CI, ELV, HUM, MOH cited (WSJ, Jun 23).
• Ex-US, UK MHRA approved Novo Nordisk's once-daily oral Wegovy tablet (Jun 11); AstraZeneca's oral GLP-1 elecoglipron posted 11.8% weight loss at 36 weeks in VISTA Phase IIb (Jun 8).

8. Week Ahead: Catalysts to Watch